
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) has received mixed reviews from various experts, highlighting both its strengths and concerns. Many praise the company for its solid performance in Asia and wealth management, coupled with a healthy dividend yield, making it an attractive income stock. However, some analysts express caution due to overvaluation, suggesting that MFC may be overbought, trading at over 2x book value with slow earnings growth of around 8-9%. While the stock is seen as a reasonable long-term holding, there are calls for potential buying opportunities during market pullbacks. The general sentiment reflects a wait-and-see approach given the mixed indicators and the overall health of the financial sector.
Rising interest rates should be a bit of a tailwind for them. The demographics for people looking to annuitize their wealth in wealth management, are good for this company. He feels the new CEO is on track to continue turning the company around. Has a good understanding of the Asian/Pacific business. Dividend yield of 3.1%. (Analysts' price target is $30.)
This is going to have the same backdrop and look a little like Toronto Dominion (TD-T) and a lot of the banks. Chart shows a little downtrend. Insurance companies did get a little soft, because they are not pure financials. This is a good stock to hold. These benefit from a strong market. If it got a little lower, around the mid-$25, that would be a good place to step in.
This is very interesting and has a very strong franchise in Asia. They have some very good high ROE Canadian businesses. The big decision for them is a need to get out of the US business and drive their ROE higher. If they can do that, the stock will do much, much better. A great story and pays a good dividend yield.
This has been a gift that keeps giving. It has done very well over the last few years. He has this trading at 11.1 2018 versus Sun Life (SLF-T) at 11.4. There has been convergence amongst all the insurance companies in Canada. To him, this is a good deal. He models it growing at 9% with a 13% dividend growth. Good balance sheet. On a little bit of a pullback, you could buy this.
(A Top Pick Feb 1/17. Up 11%.) The life insurance industry is very well positioned to take advantage if we have rising rates going forward. This company has always been particularly adept at placing itself in Asia where there is a tremendous amount of growth. Well diversified. With the new CFO, he thinks they are going to pay attention to some of the legacy problems they've had in the US. Overall, he expects profitability and margins will have a very good chance of increasing fairly significantly over the next while. This is still a Buy.
(A Top Pick Nov 18/16. Up 21%.) He still likes the insurers. Trading at 1.4X Price to Book which is not bad. 3% dividend yield, with a decent healthy growth rate. Rising interest rates and a stronger economy is going to help insurers like this. They are diversified into the Asian space, which should help them longer-term. A solid, steady name going forward.
He would prefer it a little cheaper, perhaps $24-$25. He likes this longer-term. Good business and good growth in Asia. The question is, can they offload some of their poorer US businesses. Overall, this is a good company. They increased their dividend last year by about 10%, and he expects another increase this year. (See Top Picks)
Except for the nasty bump in 2008, this was like a "buy and forget it" type of company. Always had a dividend increase every year. Record earnings. The last few years have been ugly in terms of taking write-downs, they are still making a lot of money. He likes their Asian exposure. He wouldn't sell.